On March 27, A-shares experienced fluctuating upward movement. By the midday close, the Shanghai Composite Index rose 0.26% to 3,899.12 points. The Shenzhen Component Index increased by 0.93%, while the ChiNext Index advanced 0.83%. The Beijing Stock Exchange 50 Index declined 0.06%, and the STAR Market 50 Index climbed 0.55%. The CSI A500 Index gained 0.65%. The half-day trading volume for A-shares reached 1.15 trillion yuan.
In terms of liquidity, the central bank announced it conducted a 146.2 billion yuan 7-day reverse repo operation on March 27 at a fixed interest rate of 1.40%, with both the bid amount and awarded amount totaling 146.2 billion yuan. Wind data showed 20.5 billion yuan in reverse repos matured on the same day, resulting in a net injection of 125.7 billion yuan for the day.
Regarding market news, Cheng Hehong, chief lawyer of the China Securities Regulatory Commission, stated that the financial law draft is currently open for public comment. It explicitly supports medium- to long-term capital entering the market to enhance the intrinsic stability of the capital markets, further strengthening the legal foundation for rational, value, and long-term investing.
Yu Weining, chief statistician at the National Bureau of Statistics' industry department, indicated that in January-February, various regions and departments accelerated the implementation of more proactive and effective macro policies. Efforts focused on integrating the effects of existing and incremental policies, leading to accelerated profit growth in industrial enterprises above a designated size. Most industries saw profit recovery, with equipment manufacturing and high-tech manufacturing posting rapid profit growth, reflecting a continued improvement in industrial enterprise performance. The next phase will involve thoroughly implementing the directives from the Central Economic Work Conference and the National Two Sessions, continuously expanding domestic demand, optimizing supply, developing new quality productive forces according to local conditions, deepening the construction of a unified national market, and promoting sustained healthy development of the industrial economy.
Sector-wise, due to the escalating export ban on lithium ore from Zimbabwe, new energy sectors such as lithium mining and batteries performed strongly. Stocks like Rongjie Shares, Jiangte Electric Motors, Shengxin Lithium Energy, and Jinyuan Shares saw significant gains. Innovative drug concept stocks surged, with many, including Minopharm, Jinyao Pharmaceutical, Lianhuan Pharmaceutical, and Zhaoyan New Drugs, hitting the daily limit up.
Looking at the performance of innovative drugs, CDMO growth guidance appears most clear and robust, while clinical CRO guidance generally points to moderate to steady growth, relying more on internal system optimization for profit improvement. On the other hand, since the beginning of the year, both business development and recent key project data readings have continuously reinforced the logic of enhanced competitiveness for domestic innovative drugs.
Here, by integrating the latest research reports from over 10 securities firms including Tianfeng, Anxin, and Guoxin, brief introductions to four companies are provided for reference.
1. Yinoss: As one of the earliest companies in China to simultaneously hold NMPA/OECD/FDA GLP certifications, it aligns with international standards and possesses competitive international service capabilities.—Kaiyuan Securities
2. Zhaoyan New Drugs: The company is an internationally competitive preclinical CRO firm, focusing on distinctive non-clinical safety evaluation, clinical trial services, and experimental model supply.—Industrial Securities
3. Minopharm: The company is concurrently exploring platform expansion directions, currently focusing research on peptide and enzyme-related application areas, targeting mature, harmless, or low-side-effect targets.—Tianfeng Securities
4. Biocytogen: As a globally leading platform-based biotechnology company, its RenMice platform is expected to contribute high flexibility potential, while the BioMice platform may provide stable cash flow, highlighting strong medium- to long-term growth prospects.—Cinda Securities
Comments